Press Release
OB Holdings Signs Groundbreaking LOIs With CSPC To Explore Strategic Collaboration
Orient Biotech signed two Letters of Intent with subsidiaries of CSPC to explore the joint development of specialised functional raw materials.
PETALING JAYA, 02 May 2025 – OB Holdings Berhad (“OB Holdings” or the “Company”), a leading fortified food and beverages (“F&B”) and dietary supplements manufacturing services provider in Malaysia, is pleased to announce that its wholly-owned subsidiary, Orient Biotech Sdn. Bhd. (“Orient Biotech”), has entered into two separate Letters of Intent (“LOIs”) with CSPC Innovation Pharmaceutical Co., Ltd. and CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., both subsidiaries of CSPC Pharmaceutical Group Limited (“CSPC”) (HKEX: 1093).
Listed on the Hong Kong Stock Exchange with a market capitalisation of approximately HKD71.69 billion and revenue of RMB29.01 billion in FYE2024, CSPC is a prominent Chinese pharmaceutical group known for its strong portfolio of innovative drugs and high-quality bulk ingredients. CSPC’s key therapeutic focus areas include neurology, oncology, anti-infectives, and cardiovascular disease, anchored by leading brands such as NBP, Domeisu, Jinyouli, Keaili, and Xuanning. It also manufactures essential bulk products like vitamin C, antibiotics, and caffeine series, supported by integrated R&D and manufacturing facilities in Shijiazhuang, Hebei.
The LOIs, signed on 02 May 2025, establish a collaborative framework for both parties to jointly develop specialised functional raw materials by leveraging their respective technological strengths. The collaboration aims to enhance product competitiveness, foster innovation, and expand applications within the functional food and supplement sectors across regional markets.
The LOIs will remain valid for 12 months from the date of execution.
Mr. Teoh Eng Sia, Managing Director of OB Holdings Berhad commented, "The signing of these Letters of Intent marks an exciting step forward for OB Holdings as we deepen our upstream capabilities and explore new opportunities in functional ingredients. We are confident that our collaboration with CSPC, a highly respected leader in pharmaceutical innovation, will pave the way for greater product advancement and value creation for our customers.”
Steven Wang Tao, Director of CSPC, added, “We are optimistic about the synergies this partnership will bring. CSPC’s pharmaceutical expertise, combined with Orient Biotech’s manufacturing capabilities and market understanding, opens up exciting opportunities to co-develop impactful nutritional solutions.”
This strategic development underscores OB Holdings’ continued efforts to strengthen its R&D capabilities, deepen its upstream integration, and build long-term value across its fortified F&B and health supplement value chain.
The Company will make further announcements as the collaboration progresses.
OB Holdings Berhad (“OB Holdings” or the “Company”), through its subsidiaries, specialises in the manufacturing of fortified food and beverage (“F&B”) products and dietary supplements for third-party brand owners. The Company also develops, markets, and sells its own range of fortified F&B products and dietary supplements under various house brands, including Bonlife, GoHerb, Zen Night, Sleepin’ Beaute, EZ:Nitez, Beyoute, Zen Youte, and Zenliv. Additionally, OB Holdings offers contract packing services for products such as vegetable softgel supplements, milk powder, tea leaves, honey, herb powder, fruit powder, and liquid chlorophyll in retail packaging sizes, alongside the trading of milk powder and related activities.
For more information, visit www.orient.com.my